贝伐单抗治疗晚期非小细胞肺癌的疗效与安全性临床研究进展

抗血管生成治疗是肿瘤常见的治疗方式之一。贝伐单抗作为抗血管内皮生长因子的单克隆抗体，是目前唯一被批准用于晚期非小细胞肺癌（non-small cell lung cancer，NSCLC）一线治疗的抗血管生成制剂。为了扩大贝伐单抗用于晚期NSCLC的适应证，大量研究继续探索贝伐单抗在一线治疗的联合形式外，还致力于探索其在后线及跨线治疗的疗效和安全性。本文就近年来贝伐单抗用于晚期NSCLC治疗的疗效与安全性临床研究进展进行综述。 

Clinical research progress on the efficacy and safety of bevacizumab in treating ad-vanced non-small cell lung cancer

Antiangiogenesis therapy is one of the most common anticancer therapies. Bevacizumab is a monoclonal antibody that blocks the binding of the vascular endothelial growth factor to its high-affinity receptors. It is the only antiangiogenic agent approved for the first-line treatment of advanced non-small cell lung cancer (NSCLC). Many recent studies have attempted to determine the suit-able partners of bevacizumab in first-line treatment of NSCLC and evaluate its efficacy and safety as a second-line or beyond and con-tinuous treatment of beyond disease progression in patients with advanced NSCLC. This review summarizes current clinical research about the efficacy and safety of bevacizumab in the treatment of advanced NSCLC.